Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Lazzarin

Showing results (271-280 of 288) with videos related to

Pageof 29
Sort By:
Vaccine|February 12, 2009
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-upOlimpia Longo, Antonella Tripiciano, Valeria Fiorelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2004
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational studyCristina Mussini, Patrizio Pezzotti, José M Miró, et al.
Retrovirology|June 26, 2014
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyStefania Bellino, Antonella Tripiciano, Orietta Picconi, et al.
Vaccine|November 3, 2009
The preventive phase I trial with the HIV-1 Tat-based vaccineBarbara Ensoli, Valeria Fiorelli, Fabrizio Ensoli, et al.
The Lancet. Infectious Diseases|February 15, 2014
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trialRichard B Pollard, Jürgen K Rockstroh, Giuseppe Pantaleo, et al.
Retrovirology|May 1, 2015
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialFabrizio Ensoli, Aurelio Cafaro, Anna Casabianca, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Clinical Immunology (Orlando, Fla.)|June 15, 2020
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, ItalyFabio Ciceri, Antonella Castagna, Patrizia Rovere-Querini, et al.
The New Microbiologica|November 12, 2014
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical DiseaseOrlando Armignacco, Massimo Andreoni, Evangelista Sagnelli, et al.
Clinical and Experimental Rheumatology|November 30, 2017
Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritisMassimo Galli, Spinello Antinori, Fabiola Atzeni, et al.
Pageof 29

Showing results (271-280 of 288) with videos related to

Sort By:
Pageof 29
Vaccine|February 12, 2009
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-upOlimpia Longo, Antonella Tripiciano, Valeria Fiorelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2004
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational studyCristina Mussini, Patrizio Pezzotti, José M Miró, et al.
Retrovirology|June 26, 2014
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyStefania Bellino, Antonella Tripiciano, Orietta Picconi, et al.
Vaccine|November 3, 2009
The preventive phase I trial with the HIV-1 Tat-based vaccineBarbara Ensoli, Valeria Fiorelli, Fabrizio Ensoli, et al.
The Lancet. Infectious Diseases|February 15, 2014
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trialRichard B Pollard, Jürgen K Rockstroh, Giuseppe Pantaleo, et al.
Retrovirology|May 1, 2015
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialFabrizio Ensoli, Aurelio Cafaro, Anna Casabianca, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Clinical Immunology (Orlando, Fla.)|June 15, 2020
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, ItalyFabio Ciceri, Antonella Castagna, Patrizia Rovere-Querini, et al.
The New Microbiologica|November 12, 2014
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical DiseaseOrlando Armignacco, Massimo Andreoni, Evangelista Sagnelli, et al.
Clinical and Experimental Rheumatology|November 30, 2017
Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritisMassimo Galli, Spinello Antinori, Fabiola Atzeni, et al.
Pageof 29